XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $117.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 297.42% from the company’s previous close.

Separately, StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th.

XOMA Trading Down 1.4 %

Shares of NASDAQ XOMA traded down $0.41 during mid-day trading on Friday, reaching $29.44. The company had a trading volume of 17,999 shares, compared to its average volume of 20,648. XOMA has a 52 week low of $13.48 and a 52 week high of $30.36. The business’s 50-day moving average is $27.49 and its 200-day moving average is $25.85. The stock has a market cap of $344.45 million, a price-to-earnings ratio of -7.51 and a beta of 0.93. The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15.

XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. The company had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million. Equities analysts expect that XOMA will post -1.42 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

A number of large investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets grew its holdings in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,266 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in XOMA in the first quarter worth about $212,000. Bank of New York Mellon Corp raised its position in shares of XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.